{"id":50440,"date":"2025-12-11T22:08:58","date_gmt":"2025-12-11T14:08:58","guid":{"rendered":"https:\/\/flcube.com\/?p=50440"},"modified":"2025-12-11T22:09:00","modified_gmt":"2025-12-11T14:09:00","slug":"zealand-pharma-and-otr-therapeutics-seal-2-5-billion-metabolic-disease-partnership","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50440","title":{"rendered":"Zealand Pharma and OTR Therapeutics Seal $2.5\u202fBillion Metabolic Disease Partnership"},"content":{"rendered":"\n<p><strong>OTR Therapeutics<\/strong> announced a strategic collaboration and licensing agreement with <strong>Zealand Pharma A\/S<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ZEAL:CPH\">NASDAQ: ZEAL<\/a>) to discover and develop multiple novel therapeutics for <strong>metabolic diseases<\/strong>. Zealand will pay <strong>$20\u202fmillion upfront<\/strong> (with <strong>$10\u202fmillion supplement<\/strong> upon milestones) and up to <strong>$2.5\u202fbillion<\/strong> in downstream payments plus royalties.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-structure\">Transaction Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD 20\u202fmillion<\/td><\/tr><tr><td><strong>Supplemental Upfront<\/strong><\/td><td>USD 10\u202fmillion upon predefined conditions<\/td><\/tr><tr><td><strong>Total Upfront<\/strong><\/td><td><strong>USD 30\u202fmillion<\/strong><\/td><\/tr><tr><td><strong>Development Milestones<\/strong><\/td><td>Up to USD 850\u202fmillion<\/td><\/tr><tr><td><strong>Regulatory Milestones<\/strong><\/td><td>Up to USD 650\u202fmillion<\/td><\/tr><tr><td><strong>Commercial Milestones<\/strong><\/td><td>Up to USD 1.0\u202fbillion<\/td><\/tr><tr><td><strong>Total Potential Value<\/strong><\/td><td><strong>USD 2.5\u202fbillion<\/strong><\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered, single\u2011digit % on global net sales<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Worldwide (Zealand leads development &amp; commercialization)<\/td><\/tr><tr><td><strong>Duration<\/strong><\/td><td>Multi\u2011program collaboration; individual program terms may vary<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-collaboration-scope-amp-responsibilities\">Collaboration Scope &amp; Responsibilities<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Party<\/th><th>Role<\/th><\/tr><\/thead><tbody><tr><td><strong>OTR Therapeutics<\/strong><\/td><td>\u2022 Lead discovery and preclinical development using proprietary platform<br>\u2022 Nominate development candidates for IND\u2011enabling studies<br>\u2022 Support technology transfer to Zealand<\/td><\/tr><tr><td><strong>Zealand Pharma<\/strong><\/td><td>\u2022 Global clinical development (Phase\u202f1\u20113)<br>\u2022 Regulatory submissions (FDA, EMA, NMPA)<br>\u2022 Global commercialization and marketing<\/td><\/tr><tr><td><strong>Joint Governance<\/strong><\/td><td>R&amp;D steering committee; equal representation on program oversight<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For OTR:<\/strong> Validates its <strong>drug discovery platform<\/strong> with a premier metabolic\u2011focused partner; secures <strong>non\u2011dilutive capital<\/strong> to expand internal R&amp;D while retaining <strong>downside across multiple shots on goal<\/strong>.<\/li>\n\n\n\n<li><strong>For Zealand:<\/strong> Bolsters pipeline in <strong>obesity, diabetes, and MASH<\/strong> after its <strong>GLP\u20111\/GIP\/Glucagon<\/strong> programs; leverages OTR\u2019s <strong>novel target biology<\/strong> to complement internal peptide engineering capabilities.<\/li>\n\n\n\n<li><strong>Market Context:<\/strong> Global metabolic disease market exceeds <strong>$150\u202fbillion<\/strong> (2025), driven by obesity and diabetes; oral small\u2011molecule GLP\u20111R agonists and next\u2011generation incretin modulators represent <strong>$25\u202fbillion<\/strong> opportunity by 2030. OTR\u2019s platform addresses <strong>target classes beyond incretins<\/strong>, including <strong>mitochondrial modulators<\/strong> and <strong>liver\u2011fat metabolism pathways<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-amp-next-milestones\">Pipeline &amp; Next Milestones<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Program<\/th><th>Target\/Mechanism<\/th><th>Stage<\/th><th>Expected IND<\/th><\/tr><\/thead><tbody><tr><td><strong>Program\u202f1<\/strong><\/td><td>Undisclosed mitochondrial target<\/td><td>Lead optimization<\/td><td>H2\u202f2027<\/td><\/tr><tr><td><strong>Program\u202f2<\/strong><\/td><td>Novel lipid\u2011metabolism modulator<\/td><td>Hit\u2011to\u2011lead<\/td><td>H1\u202f2028<\/td><\/tr><tr><td><strong>Program\u202f3<\/strong><\/td><td>Incretin pathway enhancer (non\u2011GLP\u20111R)<\/td><td>Discovery<\/td><td>H2\u202f2028<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Zealand expects to <strong>nominate first clinical candidate<\/strong> from the collaboration by <strong>Q4\u202f2026<\/strong>, triggering the <strong>$10\u202fmillion supplemental upfront payment<\/strong>.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the collaboration\u2019s financial milestones, development timelines, and market opportunities. Actual results may differ due to program attrition, regulatory hurdles, or competitive dynamics in the metabolic disease space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>OTR Therapeutics announced a strategic collaboration and licensing agreement with Zealand Pharma A\/S (NASDAQ: ZEAL)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50444,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4498,4490,2303],"class_list":["post-50440","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-nasdaq-zeal","tag-otr-therapeutics","tag-zealand-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zealand Pharma and OTR Therapeutics Seal $2.5\u202fBillion Metabolic Disease Partnership - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"OTR Therapeutics announced a strategic collaboration and licensing agreement with Zealand Pharma A\/S (NASDAQ: ZEAL) to discover and develop multiple novel therapeutics for metabolic diseases. Zealand will pay $20\u202fmillion upfront (with $10\u202fmillion supplement upon milestones) and up to $2.5\u202fbillion in downstream payments plus royalties.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50440\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zealand Pharma and OTR Therapeutics Seal $2.5\u202fBillion Metabolic Disease Partnership\" \/>\n<meta property=\"og:description\" content=\"OTR Therapeutics announced a strategic collaboration and licensing agreement with Zealand Pharma A\/S (NASDAQ: ZEAL) to discover and develop multiple novel therapeutics for metabolic diseases. Zealand will pay $20\u202fmillion upfront (with $10\u202fmillion supplement upon milestones) and up to $2.5\u202fbillion in downstream payments plus royalties.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50440\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-11T14:08:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-11T14:09:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50440#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50440\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zealand Pharma and OTR Therapeutics Seal $2.5\u202fBillion Metabolic Disease Partnership\",\"datePublished\":\"2025-12-11T14:08:58+00:00\",\"dateModified\":\"2025-12-11T14:09:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50440\"},\"wordCount\":375,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50440#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1101.webp\",\"keywords\":[\"NASDAQ: ZEAL\",\"OTR Therapeutics\",\"Zealand Pharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50440#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50440\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50440\",\"name\":\"Zealand Pharma and OTR Therapeutics Seal $2.5\u202fBillion Metabolic Disease Partnership - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50440#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50440#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1101.webp\",\"datePublished\":\"2025-12-11T14:08:58+00:00\",\"dateModified\":\"2025-12-11T14:09:00+00:00\",\"description\":\"OTR Therapeutics announced a strategic collaboration and licensing agreement with Zealand Pharma A\\\/S (NASDAQ: ZEAL) to discover and develop multiple novel therapeutics for metabolic diseases. Zealand will pay $20\u202fmillion upfront (with $10\u202fmillion supplement upon milestones) and up to $2.5\u202fbillion in downstream payments plus royalties.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50440#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50440\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50440#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1101.webp\",\"width\":1080,\"height\":608,\"caption\":\"Zealand Pharma and OTR Therapeutics Seal $2.5\u202fBillion Metabolic Disease Partnership\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50440#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zealand Pharma and OTR Therapeutics Seal $2.5\u202fBillion Metabolic Disease Partnership\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zealand Pharma and OTR Therapeutics Seal $2.5\u202fBillion Metabolic Disease Partnership - Insight, China&#039;s Pharmaceutical Industry","description":"OTR Therapeutics announced a strategic collaboration and licensing agreement with Zealand Pharma A\/S (NASDAQ: ZEAL) to discover and develop multiple novel therapeutics for metabolic diseases. Zealand will pay $20\u202fmillion upfront (with $10\u202fmillion supplement upon milestones) and up to $2.5\u202fbillion in downstream payments plus royalties.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50440","og_locale":"en_US","og_type":"article","og_title":"Zealand Pharma and OTR Therapeutics Seal $2.5\u202fBillion Metabolic Disease Partnership","og_description":"OTR Therapeutics announced a strategic collaboration and licensing agreement with Zealand Pharma A\/S (NASDAQ: ZEAL) to discover and develop multiple novel therapeutics for metabolic diseases. Zealand will pay $20\u202fmillion upfront (with $10\u202fmillion supplement upon milestones) and up to $2.5\u202fbillion in downstream payments plus royalties.","og_url":"https:\/\/flcube.com\/?p=50440","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-11T14:08:58+00:00","article_modified_time":"2025-12-11T14:09:00+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50440#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50440"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zealand Pharma and OTR Therapeutics Seal $2.5\u202fBillion Metabolic Disease Partnership","datePublished":"2025-12-11T14:08:58+00:00","dateModified":"2025-12-11T14:09:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50440"},"wordCount":375,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50440#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1101.webp","keywords":["NASDAQ: ZEAL","OTR Therapeutics","Zealand Pharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50440#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50440","url":"https:\/\/flcube.com\/?p=50440","name":"Zealand Pharma and OTR Therapeutics Seal $2.5\u202fBillion Metabolic Disease Partnership - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50440#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50440#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1101.webp","datePublished":"2025-12-11T14:08:58+00:00","dateModified":"2025-12-11T14:09:00+00:00","description":"OTR Therapeutics announced a strategic collaboration and licensing agreement with Zealand Pharma A\/S (NASDAQ: ZEAL) to discover and develop multiple novel therapeutics for metabolic diseases. Zealand will pay $20\u202fmillion upfront (with $10\u202fmillion supplement upon milestones) and up to $2.5\u202fbillion in downstream payments plus royalties.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50440#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50440"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50440#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1101.webp","width":1080,"height":608,"caption":"Zealand Pharma and OTR Therapeutics Seal $2.5\u202fBillion Metabolic Disease Partnership"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50440#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zealand Pharma and OTR Therapeutics Seal $2.5\u202fBillion Metabolic Disease Partnership"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1101.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50440","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50440"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50440\/revisions"}],"predecessor-version":[{"id":50445,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50440\/revisions\/50445"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50444"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50440"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}